Recent blog posts
Left ventricular noncompaction Indication Strategy Report 2026: MYH7, Trials and Deals
Latest Hotspot
8 min read
Left ventricular noncompaction Indication Strategy Report 2026: MYH7, Trials and Deals
23 July 2026
2026 Left ventricular noncompaction strategy: epidemiology, MYH7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Sinus node dysfunction Indication Strategy Report 2026: HCN4, Trials and Deals
Latest Hotspot
8 min read
Sinus node dysfunction Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Sinus node dysfunction strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Atrioventricular block Indication Strategy Report 2026: HCN4, Trials and Deals
Latest Hotspot
8 min read
Atrioventricular block Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Atrioventricular block strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Short QT syndrome Indication Strategy Report 2026: KCNH2, Trials and Deals
Latest Hotspot
8 min read
Short QT syndrome Indication Strategy Report 2026: KCNH2, Trials and Deals
23 July 2026
2026 Short QT syndrome strategy: epidemiology, KCNH2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Brugada syndrome Indication Strategy Report 2026: SCN5A, Trials and Deals
Latest Hotspot
8 min read
Brugada syndrome Indication Strategy Report 2026: SCN5A, Trials and Deals
23 July 2026
2026 Brugada syndrome strategy: epidemiology, SCN5A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Catecholaminergic polymorphic ventricular tachycardia Indication Strategy Report 2026: RYR2, Trials and Deals
Latest Hotspot
8 min read
Catecholaminergic polymorphic ventricular tachycardia Indication Strategy Report 2026: RYR2, Trials and Deals
23 July 2026
2026 Catecholaminergic polymorphic ventricular tachycardia strategy: epidemiology, RYR2 biology, clinical competition, recent deals, unmet need and market…
Read →
Long QT syndrome Indication Strategy Report 2026: KCNH2, Trials and Deals
Latest Hotspot
8 min read
Long QT syndrome Indication Strategy Report 2026: KCNH2, Trials and Deals
23 July 2026
2026 Long QT syndrome strategy: epidemiology, KCNH2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Pulmonary veno-occlusive disease Indication Strategy Report 2026: BMPR2, Trials and Deals
Latest Hotspot
8 min read
Pulmonary veno-occlusive disease Indication Strategy Report 2026: BMPR2, Trials and Deals
23 July 2026
2026 Pulmonary veno-occlusive disease strategy: epidemiology, BMPR2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Essential hypertension Indication Strategy Report 2026: AGT, Trials and Deals
Latest Hotspot
8 min read
Essential hypertension Indication Strategy Report 2026: AGT, Trials and Deals
23 July 2026
2026 Essential hypertension strategy: epidemiology, AGT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Sitosterolemia Indication Strategy Report 2026: ABCG5, Trials and Deals
Latest Hotspot
8 min read
Sitosterolemia Indication Strategy Report 2026: ABCG5, Trials and Deals
23 July 2026
2026 Sitosterolemia strategy: epidemiology, ABCG5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Read →
Familial chylomicronemia syndrome Indication Strategy Report 2026: APOC3, Trials and Deals
Latest Hotspot
8 min read
Familial chylomicronemia syndrome Indication Strategy Report 2026: APOC3, Trials and Deals
23 July 2026
2026 Familial chylomicronemia syndrome strategy: epidemiology, APOC3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Congenital hyperinsulinism Indication Strategy Report 2026: KATP, Trials and Deals
Latest Hotspot
8 min read
Congenital hyperinsulinism Indication Strategy Report 2026: KATP, Trials and Deals
23 July 2026
2026 Congenital hyperinsulinism strategy: epidemiology, KATP biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →